AARTIDRUGS Q2 FY27 Results & Earnings Analysis
Sentiment: Great (Confidence: high)
Earnings Summary
Aarti Drugs reported a milestone Q2 FY27 with record consolidated revenue of Rs. 829 crores (up 27% YoY), highest-ever EBITDA of Rs. 138 crores (up 63% YoY), and PAT of Rs. 83 crores (up 83% YoY). EBITDA margin expanded 370 bps YoY to 16.6%, and PAT margin expanded 310 bps to 10.0%. Growth was driven by 17-18% price realization improvement, 5% volume growth, and exceptional formulation exports (up 58% YoY). Management expects to sustain ~15% EBITDA margins with volume growth of 5-10% for FY27. Capacity expansions at Tarapur, Sarigam, and Baddi are underway to support future growth, with formulation business targeting Rs. 1,000 crores earlier than planned. Key risks include volume deferrals due to high prices and potential normalization of exceptional formulation margins.
Management Tone
- Prepared Remarks: Great — Prepared remarks highlighted record-breaking performance across all key metrics, with clear drivers such as price realization (16% YoY), volume growth (5%), and strategic capacity expansions. Management provided specific guidance on margin sustainability and outlined growth projects, conveying stron
- Q&A Session: Good — Q&A session was substantive, with analysts probing revenue drivers, margin sustainability, and capex plans. Management provided detailed, quantified responses on volume/price split, formulation margins, and future growth outlook, though some caution was expressed on volume growth and margin sustaina
Revenue Growth Drivers
- Firm API prices due to West Asia developments and geopolitical factors
- Volume growth constrained by high prices causing customer deferrals
- Formulation exports growth from new market entries and product registrations
Growth vs Margin Focus
Management emphasized growing volumes, improving product mix, and lowering costs through backward integration and process improvement. Targeting 5-10% volume growth while sustaining ~15% EBITDA margins with potential upside.
About Aarti Drugs Limited
Aarti Drugs Limited (AARTIDRUGS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.